AbbVie, a research─based global bio pharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a 15 mg, once─daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA)
Ook interessant voor je
Mixed Results for Paxlovid in Standard Risk Patients With COVID-19
Additional findings were announced from a phase 2/3 study evaluating the efficacy and safety of Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) in patients with COVID-19 who are at standard risk of...
Nederlandse reactie op gerichte consultatie over herziening EMA-vergoedingensysteem
Reactie op de consultatie van de Europese Commissie over het vergoedingensysteem van het Europees Geneesmiddelenagentschap (EMA).
Dit document is in het Engels.
3 x gelezen
Ahead of ASCO meet, two oncology upstarts run into difficulty
All eyes in oncology were focused expectantly last week on the tranche of clinical data that trickled out in advance of the sector’s largest and most meaningful meeting. But abstracts from the American Society of...
7 x gelezen